The Small Intestine Bacterial Overgrowth Study Pilot

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

500 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-02-15

Study Completion Date

2021-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a pragmatic study in which will compare a detailed treat-to-target (T2T) treatment algorithm to standard care for SSc SIBO at multiple sites around the world. The treatment algorithm was developed from the results of a survey of SIBO treatment preferences of rheumatologists and gastroenterologists. Although the drugs in the algorithm are already used in SSc, there is no uniform way of doing this and assessing the patient response. A very standardized protocol was created with details of how to use the medications, the duration of use and the timing of different drugs. In addition, symptoms of SIBO will be dectected by having patients complete a validated screening questionnaire, the global symptomatic score (GSS), online every 3 months for the duration of the study. A score \> 5 is very strongly related to bacterial overgrowth. In other studies, about 40% of unselected patients score at this level. This same questionnaire will be used in the T2T doctors' offices to decide if response is adequate and will also be used to assess outcome in the algorithm group versus standard care group.

The primary outcome is the change in symptoms based on the total GSS. Secondary outcomes will include examination of all GSS subscales. HRQoL will be assessed by the social scale of the newly developed UCLA SSc GIT 2.0 questionnaire, which has become the standard GI questionnaire in SSc trials.

RN. # 00296313

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Primary Prophylaxis for Spontaneous Bacterial Peritonitis

NCT04775329

Decompensated Cirrhosis Small Bowel Bacterial Overgrowth Syndrome

TERMINATED PHASE2/PHASE3

Antibiotic Treatment Trial for Small Intestinal Bacterial Overgrowth

NCT02458781

Small Intestinal Bacterial Overgrowth

UNKNOWN PHASE4

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection

NCT02589847

Clostridium Difficile Infection

COMPLETED PHASE2

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection

NCT02299570

Enterocolitis Clostridium Difficile Recurrent

COMPLETED PHASE2

Faecal Microbiota Transplantation Against Chronic Diarrhea in Patients With Systemic Sclerosis

NCT06333795

Diarrhea Systemic Sclerosis

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Objectives: To determine the feasibility of the full project. This will be a trial with 3 months of recruitment and 6 months of follow up for each case.

Specific Aims:

1. Determine if REBs perceive any major issues regarding the full trial.
2. Determine if the sites are consenting all eligible patients.
3. Determine the signing rate of consent.
4. Determine patient adherence to web access for questionnaires.
5. Assess the method for detecting eligible cases from web questionnaires.
6. Assess whether physician notifications are being sent out quickly after detecting eligible cases.
7. Assess the timeliness and completeness of physician receipt of notification of patient eligibility.
8. Assess physician adherence to treatment protocol:

1. how soon protocol patients are brought in to see doctor after receipt of notice.
2. does doctor record what he does accurately.
3. does he/she schedule return visits according to protocol.
4. does he/she use in office questionnaires for treat to target.
5. does he/she base decisions on these questionnaires.
6. does he/she follow algorithm sequentially.
9. For control sites,

1. Record how soon protocol patients are brought in to see doctor after receipt of notice.
2. Assess whether the doctor accurately records what he/she does.

10 international sites will be chosen from the INSYNC cohort located in Australia, Canada, the U.S., the Netherlands, Spain, Germany and Sweden. In each country one site will be randomly selected to be a protocol site and one standard care site. This selection will provide representation from English and non-English speaking centres and from an array of countries with different medical cultures.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Systemic Sclerosis Small Intestinal Bacterial Overgrowth

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

The primary objective of this randomized trial is to determine if a structured, treat-to-target algorithm based on treatment response and relapse performs better than standard care for the treatment of symptoms SSc-SIBO.

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Protocol Treatment

If a score on the GSS is \> 5, the computer will send an automatic notice to the office of the doctor and to the doctor him/herself telling them of this.

Upon receipt of the notice, the protocol doctors will be expected to make an appointment within the timeframe outline in the protocol. Upon receipt of this notice the secretaries or clerks at the site will be asked to insert a treatment sheet in the doctor's chart. This sheet will be used to assess the timeliness of the first visit after notification, about the adherence of protocol doctors to protocol treatment.

Group Type OTHER

Treatment Protocol

Intervention Type OTHER

Protocol treatment sites will be expected to see the patient within a pre-specified window of time. The doctors at that site will apply the treatment algorithm and will make decisions about response to treatment based on the algorithm and on specific patient answers to questionnaires. The treatment protocol will only be made available to IRBs, not to any site personnel before randomization. This was derived from a survey of rheumatologists in many countries and gastroenterologists, mostly in North America, who were asked multiple questions about how they would treat and follow up patients with suspected SIBO. Successful treatment is a response on GSS of no diarrhea plus a total GSS of \< 5.

Standard of Care

Standard care doctors, who will not know the details of this protocol, will decide on their own if and when to see the patient. Upon receipt of this notice the secretaries or clerks at the site will be asked to insert a treatment sheet in the doctor's chart. This sheet will be used to assess types of medications and general pattern of treatment of the standard of care doctors.

Group Type OTHER

Standard of Care

Intervention Type OTHER

Physicians randomly assigned to standard of care will also be informed of their patients who met eligibility criteria. They will not be aware of the detailed treatment protocol but will be informed of which medications are in the protocol eg antibiotics, prokinetics etc. They will be free to contact the patients at their convenience and to treat them in any way they deem suitable, preferably using these medications but at doses and frequencies according to their own wishes.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Treatment Protocol

Protocol treatment sites will be expected to see the patient within a pre-specified window of time. The doctors at that site will apply the treatment algorithm and will make decisions about response to treatment based on the algorithm and on specific patient answers to questionnaires. The treatment protocol will only be made available to IRBs, not to any site personnel before randomization. This was derived from a survey of rheumatologists in many countries and gastroenterologists, mostly in North America, who were asked multiple questions about how they would treat and follow up patients with suspected SIBO. Successful treatment is a response on GSS of no diarrhea plus a total GSS of \< 5.

Intervention Type OTHER

Standard of Care

Physicians randomly assigned to standard of care will also be informed of their patients who met eligibility criteria. They will not be aware of the detailed treatment protocol but will be informed of which medications are in the protocol eg antibiotics, prokinetics etc. They will be free to contact the patients at their convenience and to treat them in any way they deem suitable, preferably using these medications but at doses and frequencies according to their own wishes.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical diagnosis of Scleroderma
* Internet access
* An email address
* Adequate computer literacy in order to fill out the online questionnaires.

Exclusion Criteria

* Allergy to protocol drugs
* Concomitant disease that would make it unlikely that they will survive for one year
* Use of substances known to cause diarrhea
* History of antibiotics in the 12 weeks prior to inclusion
* History of intestinal pseudo-obstruction
* Inability to complete the symptom questionnaires
* No functional level of written \& spoken languages
* Previous C. Dificile infection
* Previous gastrointestinal surgery
* Prolonged QT interval
* Pregnancy or breastfeeding

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No